Bayer continues patent linkage battle in Delhi High Court

The Delhi High Court, on Friday directed the Drugs Controller General of India (DCGI) to continue with the process of granting a license to Cipla for the production of a generic version of Nexavar. However, division bench has directed Cipla, one of the respondents, not launch the drug without obtaining permission from the Court.